Get startedLog in
    Picture of Grifols logo

    GRF — Grifols News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapNeutral
    All News

    Brief: Grifols Doses First Patients In Two Phase 3 Trials To Expand Indications Of Immunoglobulins

    Picture of Grifols logoGrifols
    16/07/2026 09:12
    BRIEF-Grifols Doses First Patients In Two Phase 3 Trials To Expand Indications Of Immunoglobulins
    July 16 (Reuters) - Grifols SA GRLS.MC:
    • DOSES FIRST PATIENTS IN TWO PHASE 3 TRIALS TO EXPAND INDICATIONS OF ITS FLAGSHIP IMMUNOGLOBULINS
    • ONE TRIAL, SIGMA, TO EVALUATE GRIFOLS’ INTRAVENOUS IMMUNOGLOBULIN (IG) GAMUNEX®-C
    • SECOND TRIAL, XPERT, TO DETERMINE WHETHER GRIFOLS’ SUBCUTANEOUS IG, XEMBIFY®
    Source text
    Further company coverage: GRLS.MC

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 567 69 66 00;))

    Recent news on Grifols

    See all news